Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells $141,404.02 in Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,061 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $34.82, for a total value of $141,404.02. Following the transaction, the chief financial officer directly owned 88,840 shares of the company’s stock, valued at $3,093,408.80. This trade represents a 4.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The shares were sold at an average price of $34.06, for a total value of $25,170.34.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The shares were sold at an average price of $31.25, for a total value of $300,000.00.

Neurogene Stock Performance

Shares of NASDAQ NGNE opened at $35.34 on Friday. The company has a market cap of $558.37 million, a price-to-earnings ratio of -7.77 and a beta of 1.68. Neurogene Inc. has a 12 month low of $15.93 and a 12 month high of $37.27. The stock has a 50-day moving average price of $29.39 and a two-hundred day moving average price of $23.33.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). On average, sell-side analysts predict that Neurogene Inc. will post -5.63 earnings per share for the current year.

Hedge Funds Weigh In On Neurogene

Several large investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares during the last quarter. Bank of America Corp DE raised its position in Neurogene by 81.6% during the 2nd quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock worth $1,426,000 after purchasing an additional 42,880 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Neurogene by 24.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock worth $88,000 after buying an additional 1,000 shares during the period. Blair William & Co. IL lifted its holdings in Neurogene by 6.4% during the 3rd quarter. Blair William & Co. IL now owns 141,820 shares of the company’s stock worth $2,458,000 after buying an additional 8,584 shares during the period. Finally, BNP Paribas Financial Markets grew its position in shares of Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after buying an additional 978 shares during the last quarter. Institutional investors own 52.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on NGNE shares. Guggenheim started coverage on shares of Neurogene in a report on Tuesday, April 28th. They set a “buy” rating and a $69.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Neurogene in a report on Tuesday, June 9th. Rodman & Renshaw initiated coverage on Neurogene in a report on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research report on Tuesday, April 21st. Finally, Canaccord Genuity Group cut their price target on Neurogene to $180.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $84.83.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.